RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells
Melanoma is a type of malignant tumor derived from melanocytes, most of which occur in the skin, and a few occur in the mucosa and choroid. BRAF mutations occur in approximately 50% of melanoma patients. Vemurafenib is a specific and potent BRAF inhibitor that significantly prolongs progression-free...
Main Authors: | Kun Zhao, Yanrong Lu, Younan Chen, Jingqiu Cheng, Wengeng Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Data in Brief |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352340920305047 |
Similar Items
-
Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma
by: Hilal Eser Öztürk, et al.
Published: (2020-01-01) -
Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
by: Castellani Elisa, et al.
Published: (2012-07-01) -
Analysis of survival at metastatic melanoma patients treated with vemurafenib: A three year single institution study
by: Gojković Zdenka, et al.
Published: (2018-01-01) -
Metastatic melanoma and vemurafenib: novel approaches
by: Ramon Andrade De Mello
Published: (2012-04-01) -
Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
by: Fedor V. Moiseyenko, et al.
Published: (2019-05-01)